What is enzalutamide?
Enzalutamide®, also called MDV3100 is a new type of hormone
therapy for men whose prostate cancer has spread to other parts of
the body (advanced prostate cancer) and
has stopped responding to other hormone therapy and chemotherapy treatments
It is taken as a tablet and works by stopping the hormone
testosterone from reaching the prostate cancer cells. Without
testosterone, the cancer cells are not able to grow, wherever they
are in the body.
In a recent clinical trial, men who received enzalutamide lived
for about four months longer than those who were given a
When will we know if it’s been approved?
National Institute for Health and Care Excellence (NICE) have
made a draft decision approving enzalutamide and will now hold a
consultation until 9 November 2013 before making a final
announcement on whether the drug will be made available.
At the moment it’s only available in England, through the Cancer Drugs Fund, for men who
haven’t had a drug called abiraterone. In the rest of the UK
it may be possible for doctors to request it from their local
health board. The Scottish Medicines
Consortium (SMC) are due to publish their decision on
enzalutamide in November 2013.